Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 14/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.34 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.34 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.34 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12179746 | 0.79 | ACHE (0.62) | ACHECHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL20997020 | 0.76 | ACHE (0.41) | ACHELMNASMN1; SMN2TSHRMEN1 | |
| SCHEMBL12107720 | 0.76 | ACHE (0.52) | ACHELMNASMN1; SMN2MEN1KMT2A | |
| SCHEMBL20353134 | 0.76 | ACHE (0.52) | ACHELMNASMN1; SMN2MEN1KMT2A | |
| SCHEMBL30080261 | 0.76 | ACHE (0.60) | ACHE | |
| SCHEMBL19239794 | 0.75 | ACHE (0.46) | ACHETSHR | |
| SCHEMBL8588602 | 0.74 | ACHE (0.60) | ACHETSHR | |
| SCHEMBL22861408 | 0.74 | EPHX1 (0.46) | ACHELMNASMN1; SMN2MEN1KMT2A | |
| SCHEMBL19249129 | 0.73 | CA2 (0.33) | TSHRMEN1KMT2A | |
| SCHEMBL14428578 | 0.72 | MEN1 (0.39) | ACHETSHRMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170233405-A1 | MAX BINDERS AS MYC MODULATORS AND USES THEREOF | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2017-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170233405-A1 | MAX BINDERS AS MYC MODULATORS AND USES THEREOF | MYC, MYCBP, MYCBP2 | ACHE 4607/4885LMNA 2047/4885SMN1; SMN2 4044/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.